Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
1101 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 41
1102 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy France 48
1103 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 64
1104 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy United Kingdom 63
1105 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 64
1106 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 58
1107 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Poland 68
1108 Apheresis Allogeneic Myelodysplastic Syndrome, Myeloproliferative Neoplasms Hematology 2025 Standard Therapy Germany 59
1109 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 56
1110 Apheresis Allogeneic Diffuse Large B-cell Lymphoma Hematology 2025 Standard Therapy Belarus 53
1111 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 60
1112 Apheresis Allogeneic Immunodeficiency – LRBA Hematology 2025 Standard Therapy Turkey 14
1113 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Poland 20
1114 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 65
1115 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 54
1116 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 75
1117 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 58
1118 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 48
1119 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 37
1120 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Chile 40
1121 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
1122 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Switzerland 65
1123 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Portugal 68
1124 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Estonia 9
1125 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 63
1126 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 67
1127 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 45
1128 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 59
1129 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 69
1130 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 64
1131 Apheresis Allogeneic Acute lymphoblastic leukemia Hematology 2025 Standard Therapy Germany 42
1132 Apheresis Autologous Primary central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
1133 Apheresis Allogeneic Myelodysplastic Syndrome/ Acute Myeloid Leukemia Hematology 2025 Standard Therapy Germany 62
1134 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 42
1135 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 55
1136 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 72
1137 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 58
1138 Apheresis Autologous Central nervous system lymphoma Hematology 2025 Standard Therapy Germany 65
1139 Apheresis Autologous Follicular lymphoma Hematology 2025 Standard Therapy Germany 67
1140 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1141 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 60
1142 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 64
1143 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Portugal 63
1144 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 67
1145 Apheresis Autologous Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 60
1146 Apheresis Autologous Hodgkin lymphoma rezidiv Hematology 2025 Standard Therapy Germany 65
1147 Apheresis Autologous Non-Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 64
1148 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 67
1149 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1150 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1151 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
1152 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 66
1153 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
1154 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 60
1155 Apheresis Allogeneic Fanconi's Anemia Hematology 2025 Standard Therapy Ukraine 6
1156 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 69
1157 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Lithuania 54
1158 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Macedonia 56
1159 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy CROATIA 64
1160 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 75
1161 Apheresis Allogeneic T-cell Lymphoma Hematology 2025 Standard Therapy NETHERLANDS 65
1162 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 65
1163 Apheresis Allogeneic Myeloid Sarcoma Hematology 2025 Standard Therapy Brazil 48
1164 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 17
1165 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy United Kingdom 13
1166 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 69
1167 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 13
1168 Apheresis Allogeneic B-cell Precursor Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Slovakia 67
1169 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 72
1170 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 52
1171 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Belgium 64
1172 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Italy 68
1173 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Canada 56
1174 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
1175 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 55
1176 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
1177 Apheresis Allogeneic Myelodysplastic disorder Hematology 2025 Standard Therapy France 63
1178 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
1179 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 20
1180 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 23
1181 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 73
1182 Apheresis Allogeneic Inherited Immune System Disorder Hematology 2025 Standard Therapy France 9
1183 Apheresis Allogeneic Lymphoma – DLBCL Hematology 2025 Standard Therapy United Kingdom 55
1184 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 61
1185 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Lithuania 58
1186 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 73
1187 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 35
1188 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2025 Standard Therapy Germany 65
1189 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 70
1190 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 66
1191 Apheresis Autologous Diffuse large B-cell lymphoma Hematology 2025 Standard Therapy Germany 42
1192 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Netherlands 65
1193 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 60
1194 Apheresis Allogeneic Post Mielofibrosis Hematology 2025 Standard Therapy Poland 66
1195 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 74
1196 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 17
1197 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 72
1198 Apheresis Allogeneic T-cell prolymphocytic leukemia Hematology 2025 Standard Therapy New Zealand 64
1199 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
1200 Apheresis Allogeneic Mielofibrosis Hematology 2025 Standard Therapy Finland 68